stockrowAlkermes plc (ALKS) vs Neurocrine Biosciences, Inc. (NBIX)
- Alkermes plc ALKS 44.61 −2.79%
- Neurocrine Biosciences, Inc. NBIX 160.47 −3.36%
Alkermes plc and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $16.2B against $7.5B — 2.2× the size. Alkermes plc has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 23.0×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 15.3%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs −0.02%) and the higher return on invested capital (17.7% vs 1.54%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 17 and Alkermes plc on 4.
Valuation
Profitability
| Metric | ALKS | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 82.89% | 97.75% | 53.51% |
| Operating margin | 3.66% | 23.96% | 0.00% |
| Net margin | (0.02%) | 18.98% | (2.45%) |
| Free cash flow margin | 13.03% | 28.09% | 0.00% |
| Return on equity | (0.02%) | 20.41% | (0.80%) |
| Return on assets | (0.01%) | 14.20% | (1.67%) |
| Return on invested capital | 1.54% | 17.65% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack